Ocumension Therapeutics
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 36.59 | -100% | -24.28 | -100% |
| P/S |
|
17.01 | 7.13 | 138.44% |
|
|
| P/BV |
|
1.44 | 3.66 | -60.74% |
|
|
| P/FCF |
|
-11.82 | -11.82 | 0.0284% |
|
|
| Ev/Ebitda |
|
-13.93 | 2.91 | -579.04% |
|
|
| Ev/S |
|
20.34 | 16.44 | 23.71% |
|
|
| Ev/FCF |
|
-9.28 | -7.89 | 17.68% |
|
|
| E/P |
|
-0.0595 | 0.0325 | -283.29% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-156.68 | -9.7 | 1515.16% | -143018.34 | -99.89% |
| ROE |
|
-13.4 | 4.42 | -403.24% |
|
|
| ROA |
|
-12.03 | 2.95 | -507.89% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
-154.15 | -11.15 | 1282.74% |
|
|
| ROCE |
|
0 | 0.1527 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0767 | 0.7677 | -109.99% | -0.5487 | -86.03% |
| Nеt Debt/Ebitda |
|
0 | 0.0174 | -100% |
|
|
| Debt/Ratio |
|
0.009 | 0.1212 | -92.54% |
|
|
| Debt/Equity |
|
0.0187 | 0.8042 | -97.67% |
|
|
| Debt/Net Income |
|
-0.0779 | 1.54 | -105.07% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 5.7 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.13 | -100% | ||
| DSI |
|
0 | 0.5838 | -100% |
|
|
| Average dividend growth |
|
0 | 3.2 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 4.95 | -100% |
|
|
| Average percentage for payments |
|
0 | 24.82 | -100% |
|
|
| Difference from average difference in sector |
|
-5.7 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
129566.84 | 1.85 | 7003512.97% | ||
| Growth impulse Ebitda in 5 years |
|
71.96 | -44.43 | -261.96% | ||
| Growth impulse Net Income in 5 years |
|
-71.06 | 58.07 | -222.37% | ||
| Growth impulse FCF in 5 years |
|
395.89 | -7.48 | -5392.65% | ||
| Growth impulse EPS in 5 years |
|
102.62 | -198.43 | -151.72% |
IP Score
4.37/10
